SBIR-STTR Award

This STTR application requests funds to support the transfer of specific biophysical and synthetic expertise from the Anderson and Wright Groups at the University of Connecticut to investigators at Promiliad Biopharma in a joint effort to develop best-in- class therapeutic agents for the treatment of cryptosporidiosis. This water-borne protozoan, Cryptosporidium spp. represents an emerging infectious disease and has been placed on NIAID's class B list of potential biodefense hazards. These efforts will focus on inhibitors of dihydrofolate reductase (DHFR), a key enzyme involved in the production of deoxythymidine monophospate and critical for the survival of the parasitic organism. Although inhibition of this enzyme has proven a successful strategy to combat malaria, bacterial infections and toxoplasmosis, there has been no success in treating cryptosporidiosis with DHFR inhibitors. The need for the development of such agents is underscored by the absence of any effective agents against Cryptosporidium. The Anderson group has recently solved the crystal structure of DHFR-TS derived from Cryptosporidium and has identified several features of the active site that can be exploited to design potent and selective inhibitors of Cryptosporidium DHFR. In collaboration with the Wright group and Promiliad Biopharma, a series of novel classes of inhibitors have been designed to display enhanced levels of potency and selectivity. Through this STTR initiative we will create moderately sized libraries of novel inhibitors though parallel synthesis, screen these libraries for potent and selective inhibitors of C. hominis DHFR using in vitro enzyme and cell culture assays. We expect to discover several novel inhibitors that will provide the foundation for Phase II research for the development of new therapeutics

This Phase II STTR proposal describes a collaborative effort between researchers in the Department of Pharmaceutical Sciences at the University of Connecticut and Promiliad Biopharma to develop efficacious antibiotics targeting both methicillin-resistant strains of Staphylococcus aureus (MRSA) and Streptococcus pyogenes. We have recently completed a Phase I STTR grant that was focused on developing agents against the parasitic protozoan Cryptosporidium hominis by targeting the essential enzyme dihydrofolate reductase (DHFR). Through this work we developed the most potent and selective inhibitors of this enzyme reported to date and showed efficacy against the cultured parasite. In parallel with these efforts targeting Cryptosporidium, we examined the generality of this compound class to inhibit DHFR from other pathogenic organisms and found that this scaffold can be customized to potently target a wide range of pathogenic DHFR enzymes, including that from MRSA and Streptococcus pyogenes. We intend to capitalize on the high-profile nature of these organisms by switching the focus of our first proof-of-concept antibiotic. We have shown that the compounds effectively inhibit the growth of various phenotypes of MRSA and Streptococcus pyogenes. Moreover, we have determined several high-resolution crystal structures of the pathogenic MRSA enzyme in complex with representative inhibitors, placing us in a strong position to further develop these new antibiotics. The efforts to develop an efficacious candidate compound will evolve through three specific aims. In the first Aim, we will complete an initial analog series and select two lead compounds to move forward into animal studies in the second specific aim. These studies will determine key pharmacokinetic parameters (bioavailability, half-life) for our compounds as well as determine efficacy in an animal model of infection. In the third specific aim, we will explore new, structure-based designs to enhance the selectivity of our compounds for the pathogenic forms of DHFR over the human homolog. Completion of these studies will position us to attract outside investors and partners to progress our compounds for an IND application.

Public Health Relevance:
Despite decades of work on the discovery of antibiotics, the continued emergence of resistance organisms threatens to render many of our best antibiotics obsolete. We are working to develop new agents against that function as effective monotherapies against the methicillin-resistant strain of Staphylococcus aureus (MRSA) and Streptococcus pyogenes. Specifically we are targeting the essential enzyme dihydrofolate reductase (DHFR) that is required by the bacteria to synthesize key components needed to replicate its genetic material.

Thesaurus Terms:
5,6,7,8-Tetrahydrofolate[{..}]nadp+ Oxidoreductase; Animal Model; Animal Models And Related Studies; Animals; Anti-Bacterial Agents; Antibacterial Agents; Antibiotic Agents; Antibiotic Drugs; Antibiotics; Antifolates; Award; Bacteria; Bioavailability; Biologic Availability; Biological; Biological Availability; Chemistry, Pharmaceutical; Collaborations; Complex; Connecticut; Cryptosporidiosis; Cryptosporidium; Dap; Dhfr; Development; Dihydrofolate Dehydrogenase; Dihydrofolate Reductase; Dose; Drug Kinetics; Ec 1.5.1.3; Enzyme Antagonist; Enzyme Inhibitor; Enzyme Inhibitor Agent; Enzyme Inhibitor Drugs; Enzyme Inhibitors; Enzymes; Evaluation; Exhibits; Folate Analog; Folate Inhibitors; Folic Acid Analog; Folic Acid Antagonists; Folic Acid Inhibitors; Folic Acid Reductase; Genehomolog; Generalized Growth; Generations; Genetic Materials; Grant; Growth; Half-Life; Half-Lifes; Homolog; Homologous Gene; Homologue; Human; Human, General; In Vitro; Infection; Investigators; Lead; Link; Man (Taxonomy); Man, Modern; Medicinal Chemistry; Methicillin Resistance; Miscellaneous Antibiotic; Montana; Nature; New Agents; Organism; Parasites; Pb Element; Pharmaceutic Chemistry; Pharmaceutical Agent; Pharmaceutical Chemistry; Pharmaceuticals; Pharmacokinetics; Pharmacologic Substance; Pharmacological Substance; Phase; Phenotype; Physiologic Availability; Position; Positioning Attribute; Property; Property, Loinc Axis 2; Protozoa; Protozoal; Reporting; Research Personnel; Researchers; Resistance; Resolution; S. Aureus; S. Pyogenes; S.Aureus; S.Pyogenes; Sttr; Science; Series; Skin; Small Business Technology Transfer Research; Soft Tissue Infections; Staging; Staphylococcus Aureus; Streptococcus Group A; Streptococcus Pyogenes; Structure; Tetrahydrofolate Dehydrogenase; Therapeutic; Tissue Growth; Universities; Work; Analog; Anti-Bacterial; Antibacterial; Base; Bioavailability Of Drug; Biodefense; Chemotherapy; Design; Designing; Diaminopyrimidine; Efficacy Evaluation; Experiment; Experimental Research; Experimental Study; Folate Antagonist; Fungus; Heavy Metal Pb; Heavy Metal Lead; Improved; In Vivo; Indexing; Inhibitor; Inhibitor/Antagonist; Lead Series; Living System; Meetings; Methicillin Resistant; Model Organism; New Therapeutics; Next Generation Therapeutics; Novel; Novel Therapeutics; Ontogeny; Pathogen; Public Health Relevance; Research Study; Resistant; Resistant Strain; Scaffold; Scaffolding